<DOC>
	<DOCNO>NCT00065442</DOCNO>
	<brief_summary>Provenge investigational product design activate man 's antigen presenting cell , type immune cell , detect prostate cancer cell initiate immune response . Having complete Phase 1 Phase 2 clinical trial , Provenge Phase 3 level . One important Phase 3 trial Provenge complete ; current trial also Phase 3 study . If decide participate eligible , enrol study randomly assign receive either active product placebo . There two chance three receive Provenge . After receive treatment , monitor regular interval study endpoint meet . At end trial , men receive placebo opportunity treat active product another study .</brief_summary>
	<brief_title>ProvengeÂ® ( Sipuleucel-T ) Active Cellular Immunotherapy Treatment Metastatic Prostate Cancer After Failing Hormone Therapy</brief_title>
	<detailed_description>The trial conduct multiple study center throughout United States . The trial double-blind , placebo-controlled trial . Participants must meet specific eligibility criterion . Study personnel determine eligibility telephone interview routine medical test ( physical exam , blood test , image scan ) do study center . If qualify decide participate trial , three product administration course one month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>To qualify trial , must ALL following : Histologically document adenocarcinoma prostate Cancer progress adequate hormone therapy . This state disease androgen independent prostate cancer ( AIPC ) . Cancer spread outside prostate ( metastatic ) lymph node bone . Please note cancer spread organ ( e.g. , liver , lung , brain ) , eligible study . The absence minimal current cancerrelated pain Please note additional eligibility criterion . The study center determine meet criterion . Study personnel explain trial detail answer question may qualify study . You decide whether wish participate . If qualify trial , study personnel explain reason .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>prostate</keyword>
	<keyword>AIPC</keyword>
	<keyword>androgen-independent</keyword>
	<keyword>androgen independent</keyword>
	<keyword>hormone insensitive</keyword>
	<keyword>hormone-insensitive</keyword>
	<keyword>PSA</keyword>
	<keyword>prostatic adenocarcinoma</keyword>
	<keyword>hormone-refractory</keyword>
	<keyword>hormone refractory</keyword>
	<keyword>HRPC</keyword>
	<keyword>LHRH</keyword>
	<keyword>immune therapy</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>vaccine</keyword>
	<keyword>dendritic cell</keyword>
	<keyword>antigen-presenting cell</keyword>
	<keyword>antigen present cell</keyword>
	<keyword>cancer vaccine</keyword>
	<keyword>therapeutic vaccine</keyword>
	<keyword>therapeutic cancer vaccine</keyword>
	<keyword>recombinant</keyword>
	<keyword>biological</keyword>
	<keyword>biopharmaceutical</keyword>
	<keyword>biotechnology</keyword>
	<keyword>biotech</keyword>
</DOC>